Form 4: Vanda Pharmaceuticals SVP Acquires 125,000 Shares of Common Stock

Gunther Birznieks, SVP of Business Development at Vanda Pharmaceuticals, acquired 125,000 shares of common stock through a restricted stock unit award.

Summary

• On February 18, 2025, Gunther Birznieks, SVP of Business Development at Vanda Pharmaceuticals, acquired 125,000 shares of common stock.
• The acquisition was through a time-based restricted stock unit (RSU) award.
• The RSU vests in four equal annual installments, starting March 1, 2026, contingent upon continuous employment with Vanda Pharmaceuticals.
• Vested shares will be delivered on the first permissible trading day after each vesting date.
• Following the transaction, Birznieks beneficially owns 438,569 shares of Vanda Pharmaceuticals.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating an executive's acquisition of shares, which can be interpreted as a positive sign of confidence but doesn't inherently indicate strong positive or negative sentiment.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the RSU is contingent upon the reporting person's continued employment with the issuer.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the trading activities of company insiders. This filing indicates an executive's increased stake in the company, which is often viewed positively by investors.

Key Dates

Keywords

Vanda Pharmaceuticals, Gunther Birznieks, Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Unit, VNDA, SVP Business Development